Chiron lowers Fluvirin production estimate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron will produce 18 mil. to 20 mil. doses of its influenza vaccine Fluvirin for the 2005-06 flu season, the company says June 15. The firm previously projected its production level would be 25 mil. to 30 mil. doses (1Pharmaceutical Approvals Monthly June 2005, In Brief). Chiron expects FDA to inspect its manufacturing facility this month to determine whether deficiencies noted in a December 2004 warning letter have been resolved. GlaxoSmithKline plans to provide 10 mil. doses of its flu vaccine Fluarix for the 2005-06 season; the firm submitted the Fluarix BLA May 25...
You may also be interested in...
GSK Fluarix submission
GlaxoSmithKline anticipates an expedited review for its influenza vaccine Fluarix; the company submitted a BLA May 25. GSK has begun a manufacturing ramp-up aimed at providing 10 mil. doses of the vaccine for the 2005-06 flu season. Competitor Chiron, whose Fluvirin was removed from the market last season due to manufacturing issues, expects to begin shipping 25 mil. to 30 mil. doses of its product in the third quarter; the firm said FDA is slated to inspect its manufacturing facility in mid-June to late July...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.